Juno Therapeutics is a technology company.
Juno Therapeutics has raised $306.0M across 3 funding rounds.
Juno Therapeutics has raised $306.0M in total across 3 funding rounds.
# Juno Therapeutics: A Biopharmaceutical Pioneer, Not a Technology Company
Juno Therapeutics is a biopharmaceutical company, not a technology company. The premise of your query contains an inaccuracy that's worth clarifying upfront, as it shapes how we should understand this organization's role in the broader landscape.
Juno Therapeutics Inc. was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, and Seattle Children's Research Institute.[1] The company specialized in developing cell-based cancer immunotherapies, specifically using chimeric antigen receptor (CAR-T) and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.[3]
Juno's mission was to advance adoptive T-cell therapies aimed at curing a broad range of cancers, initially focusing on blood cancers including leukemia, acute and aggressive lymphomas, and B-cell lymphomas.[2] The company targeted patients with advanced disease who had not responded to chemotherapy, radiation, and transplants—populations with limited treatment options. Rather than operating as a standalone venture, Juno was designed as a commercial enterprise to accelerate the translation of cutting-edge research from three world-renowned institutions into clinical practice.[2]
Juno was launched in 2013 with $120 million in private investment funding, making it one of the largest Series A biotech startups in history.[2] Its primary investors were ARCH Venture Partners and the Alaska Permanent Fund.[2] The company's founding was driven by the recognition that adoptive T-cell therapies held enormous potential to save lives, and that in an environment of limited public research funding, a commercial venture backed by experienced investors and seasoned management offered the fastest path to clinical translation.[2]
The company's early traction was notable: by the time of its public launch, approximately two dozen patients had been treated across the three founding institutions, with promising outcomes including many cases of remission in patients with advanced-stage cancer.[2] This clinical validation—combined with the intellectual property and scientific expertise embedded in the founding institutions—gave Juno substantial credibility from inception. The company subsequently achieved the second-fastest $1 billion IPO valuation ever, behind only YouTube.[4]
Juno emerged at a pivotal moment in cancer immunotherapy. The early 2010s saw growing clinical validation of CAR-T cell therapy as a transformative approach to treating previously intractable blood cancers. Juno's founding represented a deliberate effort to bridge the gap between academic discovery and commercial development—taking proven science from leading research institutions and scaling it into a drug development enterprise.
The company's success (reflected in its rapid IPO and eventual $9 billion acquisition by Celgene in 2018) validated the model of translating institutional research into commercial biopharmaceutical ventures.[1] This influenced how major research centers approached commercialization of their discoveries in subsequent years.
Juno Therapeutics no longer exists as an independent entity. On January 22, 2018, Juno was acquired by Celgene for $9 billion, and in November 2019, Bristol-Myers Squibb completed its acquisition of Celgene.[1] This consolidation reflected the capital intensity of bringing cell-based immunotherapies to market and the strategic value of Juno's pipeline to larger pharmaceutical players.
The company's legacy lies in demonstrating that CAR-T cell therapy could be successfully commercialized and that institutional research collaborations could generate substantial value. Its acquisition by BMS positioned Juno's therapies within one of the world's largest pharmaceutical companies, potentially accelerating their development and market reach—though as a subsidiary, Juno's independent influence on the biotech ecosystem has diminished since its acquisition.
Juno Therapeutics has raised $306.0M in total across 3 funding rounds.
Juno Therapeutics's investors include Advanced Technology Ventures, ARCH Venture Partners, Flagship Ventures, OrbiMed, Polaris Partners, Venrock.
Juno Therapeutics has raised $306.0M across 3 funding rounds. Most recently, it raised $130.0M Series B in August 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2014 | $130.0M Series B | Advanced Technology Ventures, ARCH Venture Partners, Flagship Ventures, OrbiMed, Polaris Partners, Venrock | |
| Apr 1, 2014 | $56.0M Series A | Advanced Technology Ventures, OrbiMed, Polaris Partners, Venrock | |
| Dec 1, 2013 | $120.0M Series A | ARCH Venture Partners, Flagship Ventures |